Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-10-11, Stock:LLY, The news for the past five days is as follows:
2018-10-04: NEWS1: Alphabet and Simon Property skid while Constellation rises.NEWS2: Tech Stocks Punished As Nasdaq Breaks Support; Leading Software Stocks Nailed.NEWS3: Notable Thursday Option Activity: HD, LLY, ADBE.NEWS4: Notable Thursday Option Activity: HD, LLY, ADBE.NEWS5: US STOCKS-Wall St succumbs to soaring bond yields.NEWS6: XLV, UNH, MDT, LLY: ETF Inflow Alert.NEWS7: XLV, UNH, MDT, LLY: ETF Inflow Alert.NEWS8: Boehringer Ingelheim and Lilly present full results of Tradjenta®'s CARMELINA® cardiovascular outcome trial.NEWS9: S&P 500 Movers: COTY, LLY.NEWS10: S&P 500 Movers: COTY, LLY.NEWS11: Amgen’s Stock Performance and Estimates after Q3 2018.NEWS12: US STOCKS-Wall St succumbs to soaring bond yields.NEWS13: Lilly's diabetes drug data impresses, hurts rival Novo's shares.NEWS14: US STOCKS-Wall St set to open lower as Treasury yields jump.NEWS15: Diabetes Drug&apos;s Results Push Lilly to Look at Obesity Too.NEWS16: The Daily Biotech Pulse: AtriCure's Guidance, Guardant Health And Kodiak To Debut.NEWS17: Eli Lilly&apos;s stock surges toward record after positive trials for diabetes treatments.NEWS18: Eli Lilly’s Stock Performance and Estimates for Q3 2018.NEWS19: Mylan Launches Its Generic Brevibloc Injection.NEWS20: Global Markets Drag Stocks Lower; Did China Hack Apple?.NEWS21: Boehringer Ingelheim and Lilly present full results from EASE Phase III program for empagliflozin as adjunct to insulin in type 1 diabetes.NEWS22: Lilly's Investigational Dual GIP and GLP-1 Receptor Agonist Shows Significant Reduction in HbA1c and Body Weight in People With Type 2 Diabetes.NEWS23: Eli Lilly's diabetes drug shows promise in mid-stage trial.NEWS24: Boehringer Ingelheim & Eli Lilly: Empagliflozin Meets Primary Efficacy Endpoint.NEWS25: Boehringer Ingelheim & Eli Lilly: Empagliflozin Meets Primary Efficacy Endpoint.
2018-10-05: NEWS1: Cramer Remix: How this drug stock put the bear case to re....NEWS2: Market Winners & Losers.NEWS3: Eli Lilly Stock Is Climbing on Upbeat Drug Data and an Upgrade.NEWS4: Stocks Today: Tesla, Costco Hit As Nasdaq Extends Losses; 10-Year Yield Up Again.NEWS5: Company News For Oct 5, 2018.NEWS6: Company News For Oct 5, 2018.NEWS7: Lilly's Novel Diabetes Candidate Shows Promise in Phase II.NEWS8: Lilly's Novel Diabetes Candidate Shows Promise in Phase II.NEWS9: Pharma Stock Roundup: PFE to Get New CEO, LLY Presents Impressive Diabetes Data.NEWS10: Pharma Stock Roundup: PFE to Get New CEO, LLY Presents Impressive Diabetes Data.NEWS11: 3 Big Stock Charts for Friday: PPL, Macy’s and Eli Lilly.NEWS12: 3 Big Stock Charts for Friday: PPL, Macy’s and Eli Lilly.NEWS13: Company News For Oct 5, 2018.NEWS14: Pharma Stock Roundup: PFE to Get New CEO, LLY Presents Impressive Diabetes Data.NEWS15: Lilly&apos;s Novel Diabetes Candidate Shows Promise in Phase II.NEWS16: Stocks Mixed On Jobs Report, Trade Data: China's Lenovo Takes A Dive.NEWS17: Bull of the Day: Roche (RHHBY).NEWS18: Bull of the Day: Roche (RHHBY).NEWS19: The Daily Biotech Pulse: MediciNova Gets Orphan-Drug Status, KemPharm To Offer Shares, Emergent Buys Vaccine Maker.NEWS20: Today's Research Reports on Trending Tickers: Eli Lilly and Company and Mallinckrodt.NEWS21: 3 Big Stock Charts for Friday: PPL, Macy’s and Eli Lilly.
2018-10-08: NEWS1: Lilly to Present New Data From Oncology Portfolio at ESMO 2018 Congress, Showcasing Patient-Centric Advances in Cancer Care.NEWS2: Is Franklin LibertyQ U.S. Equity ETF (FLQL) a Hot ETF Right Now?.NEWS3: Is Franklin LibertyQ U.S. Equity ETF (FLQL) a Hot ETF Right Now?.NEWS4: Is Franklin LibertyQ U.S. Equity ETF (FLQL) a Hot ETF Right Now?.
2018-10-09: NEWS1: 4 Reasons to Be Wary of This Animal Health IPO.NEWS2: 4 Reasons to Be Wary of This Animal Health IPO.NEWS3: Lilly's Investigational Dual GIP and GLP-1 Receptor Agonist Shows Significant Reduction in HbA1c and Body Weight in People With Type 2 Diabetes.NEWS4: 4 Reasons to Be Wary of This Animal Health IPO.NEWS5: A Look at Novartis’s Valuation on October 9.NEWS6: Assessing Novartis’s Performance in October So Far.NEWS7: 5 Companies Hit 52-Week Highs.NEWS8: A Walk-Through of Eli Lilly’s Alzheimer’s Disease Portfolio.
2018-10-10: NEWS1: The Daily Biotech Pulse: Novartis Blood Disorder Drug Improves Patient Outcomes, Audentes To Offer Shares.NEWS2: New analysis estimates the positive impact of Jardiance® on life expectancy in adults with type 2 diabetes and established cardiovascular disease.

Answer: Decrease